How often does elastran need to be injected?

Elacestrant is a novel oral selective estrogen receptor degrader (SERD) for the treatment of advanced breast cancer in postmenopausal women with hormone receptor-positive (HR+), HER2-negative, and ESR1 mutations. This type of breast cancer patients gradually become resistant to traditional endocrine therapy, especially when ESR1 mutations are present, and the effect of therapies such as aromatase inhibitors is significantly weakened. The mechanism of action of Elacestrant is to selectively bind and degrade mutated estrogen receptors, fundamentally interfering with tumor cell proliferation signals. It is a breakthrough in the treatment of ESR1 mutant breast cancer.

The currently approved trade name isORSERDU, which was approved for marketing by the US FDA in early 2023. It is the first oral targeted endocrine drug for ESR1-mutated breast cancer. This innovation breaks the limitation that traditional SERD must be injected intramuscularly. Unlike Fulvestrant, which was commonly used in the past, elastrant is an oral tablet and no longer requires monthly or biweekly injections, greatly improving medication convenience and patient compliance.

The recommended usage of ORSERDU is 345 mg orally once daily, which must be taken with food. The taking time should be fixed at the same time every day to stabilize the blood concentration. Since elastran is an oral drug, there is no "one injection" interval problem. Patients only need to take the medication regularly every day until the disease progresses or intolerable side effects occur.

It is worth noting that if you vomit or miss taking the medicine for more than 6 hours during the medication, do not take the dose again, but continue the original dose the next day to avoid dose accumulation or drug effect disorder. In addition, taking it with food can significantly reduce gastrointestinal adverse reactions, such as nausea, loss of appetite, etc., and help improve patients' willingness to continue taking the medication.

In general,The advent of Elacestrant represents a new era of oral SERD, providing a more convenient and effective treatment option for patients with ESR1 mutant breast cancer, and also indicates that personalized treatment of breast cancer has entered a more refined stage.

References:https://www.drugs.com/mtm/elacestrant.html